Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cervical Cancer-Pipeline Review, H1 2015

Cervical Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cervical Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cervical Cancer-Pipeline Review, H1 2015', provides an overview of the Cervical Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cervical Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cervical Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Cervical Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Cervical Cancer-Overview 11

Pipeline Products for Cervical Cancer-Comparative Analysis 12

Cervical Cancer-Therapeutics under Development by Companies 13

Cervical Cancer-Therapeutics under Investigation by Universities/Institutes 18

Cervical Cancer-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Unknown Stage Products 23

Cervical Cancer-Products under Development by Companies 24

Cervical Cancer-Products under Investigation by Universities/Institutes 29

Cervical Cancer-Companies Involved in Therapeutics Development 31

3SBio Inc. 31

Admedus Ltd 32

Advaxis, Inc. 33

Amorfix Life Sciences Ltd. 34

Antigen Express, Inc. 35

Arbor Vita Corporation 36

AstraZeneca Plc 37

AVEO Pharmaceuticals, Inc. 38

Azaya Therapeutics Incorporated 39

Cancer Research Technology Limited 40

Chong Kun Dang Pharmaceutical Corp. 41

Critical Outcome Technologies Inc. 42

CZ BioMed Corp 43

Daiichi Sankyo Company, Limited 44

EyeGene, Inc. 45

F. Hoffmann-La Roche Ltd. 46

Formune S.L. 47

Genexine, Inc. 48

Genmab A/S 49

Genticel S.A. 50

GlaxoSmithKline Plc 51

Indian Immunologicals Limited 52

Inovio Pharmaceuticals, Inc. 53

ISA Pharmaceuticals B.V. 54

Karyopharm Therapeutics, Inc. 55

Kite Pharma, Inc. 56

LondonPharma Ltd 57

MedImmune, LLC 58

MEI Pharma, Inc. 59

Nanotherapeutics, Inc. 60

Nektar Therapeutics 61

Novartis AG 62

Oncobiologics, Inc. 63

Otsuka Holdings Co., Ltd. 64

Redbiotec AG 65

Rexahn Pharmaceuticals, Inc. 66

Sanofi 67

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 68

Shantha Biotechnics Limited 69

Sirnaomics, Inc. 70

Taiho Pharmaceutical Co., Ltd. 71

Theravectys S.A. 72

Vaccibody AS 73

VLPbio 74

Zeria Pharmaceutical Co Ltd 75

Zydus Cadila Healthcare Limited 76

Cervical Cancer-Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Combination Products 78

Assessment by Target 79

Assessment by Mechanism of Action 83

Assessment by Route of Administration 86

Assessment by Molecule Type 88

Drug Profiles 90

(tegafur + gimeracil + oteracil)-Drug Profile 90

ADXS-HPV-Drug Profile 93

AEH-10p-Drug Profile 97

AMF-3d19-Drug Profile 98

aminolevulinic acid hydrochloride-Drug Profile 99

Antisense Oligonucleotides for Cervical Cancer-Drug Profile 100

Aptamer to Target HPV E7 Protein for Cervical Cancer-Drug Profile 101

artemether-Drug Profile 102

AV-203-Drug Profile 104

AVC-7-Drug Profile 105

AZD-1775-Drug Profile 106

AZD-5363-Drug Profile 108

bevacizumab-Drug Profile 110

bevacizumab biosimilar-Drug Profile 115

bevacizumab biosimilar-Drug Profile 116

BLI-1004-Drug Profile 117

BPR-1K653-Drug Profile 118

buparlisib hydrochloride-Drug Profile 119

Cell Therapy for Cervical Carcinoma-Drug Profile 123

Cell Therapy for HPV Associated Cancers-Drug Profile 124

Cell Therapy to Target HPV-16 E6 Protein for Cancer-Drug Profile 125

Cell Therapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer-Drug Profile 127

CerviVax-Drug Profile 129

Cervlysis-Drug Profile 130

CIGB-228-Drug Profile 131

CIGB-300-Drug Profile 132

CKD-12201-Drug Profile 134

COTI-2-Drug Profile 135

crocetin-Drug Profile 138

docetaxel liposomal-Drug Profile 140

durvalumab + tremelimumab-Drug Profile 142

EDA-HPVE7-Drug Profile 144

EG-HPV-Drug Profile 145

etirinotecan pegol-Drug Profile 146

everolimus-Drug Profile 149

GSK-2849330-Drug Profile 155

GX-188E-Drug Profile 156

human papillomavirus vaccine-Drug Profile 157

human papillomavirus vaccine-Drug Profile 158

human papillomavirus vaccine-Drug Profile 159

human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar-Drug Profile 161

HuMax-TF-ADC-Drug Profile 162

INO-3112-Drug Profile 163

ISA-101-Drug Profile 164

Lovaxin S-Drug Profile 165

mapatumumab-Drug Profile 166

ME-344-Drug Profile 168

nimotuzumab-Drug Profile 170

NTCP-02-Drug Profile 173

OPB-111001-Drug Profile 174

OTAC-DCtag-Drug Profile 175

patritumab-Drug Profile 176

pazopanib hydrochloride-Drug Profile 178

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Oncology-Drug Profile 184

Peptides to Inhibit Bcl-x and MCL-1 for Oncology-Drug Profile 185

ProCervix-Drug Profile 186

RA-190-Drug Profile 188

RBT-201-Drug Profile 189

RX-3117-Drug Profile 190

S-009131-Drug Profile 192

SAR-408701-Drug Profile 193

selinexor-Drug Profile 194

Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology-Drug Profile 199

Small Molecules for Cervival Cancer-Drug Profile 200

SSS-08-Drug Profile 201

STP-909-Drug Profile 202

TA-CIN-Drug Profile 203

Tenacinol-Drug Profile 205

TF-011 Monomethyl Auristatin E-Drug Profile 206

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 208

Triapine-Drug Profile 210

Vaccine for Cervical and Head and Neck Cancers-Drug Profile 212

Vaccine for Cervical Cancer-Drug Profile 213

Vaccine for Cervical Cancer-Drug Profile 214

vaccine for cervical cancer-Drug Profile 215

Vaccine for Cervical Cancer and Genital Warts-Drug Profile 216

Vaccine for Cervical Cancer, Head And Neck Cancer-Drug Profile 217

Vaccine for HPV Associated Cancers-Drug Profile 218

Vaccine for Ovarian Cancer and Cervical Cancer-Drug Profile 219

Vaccine to Target HPV E7 Protein for Cervical Cancer-Drug Profile 220

Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer-Drug Profile 221

VB-1016-Drug Profile 222

Vvax-001-Drug Profile 223

Z-100-Drug Profile 224

Cervical Cancer-Recent Pipeline Updates 225

Cervical Cancer-Dormant Projects 287

Cervical Cancer-Discontinued Products 291

Cervical Cancer-Product Development Milestones 292

Featured News & Press Releases 292

Appendix 301

Methodology 301

Coverage 301

Secondary Research 301

Primary Research 301

Expert Panel Validation 301

Contact Us 301

Disclaimer 302

List of Tables

Number of Products under Development for Cervical Cancer, H1 2015 17

Number of Products under Development for Cervical Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Comparative Analysis by Unknown Stage Development, H1 2015 29

Products under Development by Companies, H1 2015 30

Products under Development by Companies, H1 2015 (Contd..1) 31

Products under Development by Companies, H1 2015 (Contd..2) 32

Products under Development by Companies, H1 2015 (Contd..3) 33

Products under Development by Companies, H1 2015 (Contd..4) 34

Products under Investigation by Universities/Institutes, H1 2015 35

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 36

Cervical Cancer-Pipeline by 3SBio Inc., H1 2015 37

Cervical Cancer-Pipeline by Admedus Ltd, H1 2015 38

Cervical Cancer-Pipeline by Advaxis, Inc., H1 2015 39

Cervical Cancer-Pipeline by Amorfix Life Sciences Ltd., H1 2015 40

Cervical Cancer-Pipeline by Antigen Express, Inc., H1 2015 41

Cervical Cancer-Pipeline by Arbor Vita Corporation, H1 2015 42

Cervical Cancer-Pipeline by AstraZeneca Plc, H1 2015 43

Cervical Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 44

Cervical Cancer-Pipeline by Azaya Therapeutics Incorporated, H1 2015 45

Cervical Cancer-Pipeline by Cancer Research Technology Limited, H1 2015 46

Cervical Cancer-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 47

Cervical Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 48

Cervical Cancer-Pipeline by CZ BioMed Corp, H1 2015 49

Cervical Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 50

Cervical Cancer-Pipeline by EyeGene, Inc., H1 2015 51

Cervical Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 52

Cervical Cancer-Pipeline by Formune S.L., H1 2015 53

Cervical Cancer-Pipeline by Genexine, Inc., H1 2015 54

Cervical Cancer-Pipeline by Genmab A/S, H1 2015 55

Cervical Cancer-Pipeline by Genticel S.A., H1 2015 56

Cervical Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 57

Cervical Cancer-Pipeline by Indian Immunologicals Limited, H1 2015 58

Cervical Cancer-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 59

Cervical Cancer-Pipeline by ISA Pharmaceuticals B.V., H1 2015 60

Cervical Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 61

Cervical Cancer-Pipeline by Kite Pharma, Inc., H1 2015 62

Cervical Cancer-Pipeline by LondonPharma Ltd, H1 2015 63

Cervical Cancer-Pipeline by MedImmune, LLC, H1 2015 64

Cervical Cancer-Pipeline by MEI Pharma, Inc., H1 2015 65

Cervical Cancer-Pipeline by Nanotherapeutics, Inc., H1 2015 66

Cervical Cancer-Pipeline by Nektar Therapeutics, H1 2015 67

Cervical Cancer-Pipeline by Novartis AG, H1 2015 68

Cervical Cancer-Pipeline by Oncobiologics, Inc., H1 2015 69

Cervical Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 70

Cervical Cancer-Pipeline by Redbiotec AG, H1 2015 71

Cervical Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 72

Cervical Cancer-Pipeline by Sanofi, H1 2015 73

Cervical Cancer-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 74

Cervical Cancer-Pipeline by Shantha Biotechnics Limited, H1 2015 75

Cervical Cancer-Pipeline by Sirnaomics, Inc., H1 2015 76

Cervical Cancer-Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 77

Cervical Cancer-Pipeline by Theravectys S.A., H1 2015 78

Cervical Cancer-Pipeline by Vaccibody AS, H1 2015 79

Cervical Cancer-Pipeline by VLPbio, H1 2015 80

Cervical Cancer-Pipeline by Zeria Pharmaceutical Co Ltd, H1 2015 81

Cervical Cancer-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 82

Assessment by Monotherapy Products, H1 2015 83

Assessment by Combination Products, H1 2015 84

Number of Products by Stage and Target, H1 2015 86

Number of Products by Stage and Mechanism of Action, H1 2015 90

Number of Products by Stage and Route of Administration, H1 2015 93

Number of Products by Stage and Molecule Type, H1 2015 95

Cervical Cancer Therapeutics-Recent Pipeline Updates, H1 2015 231

Cervical Cancer-Dormant Projects, H1 2015 293

Cervical Cancer-Dormant Projects (Contd..1), H1 2015 294

Cervical Cancer-Dormant Projects (Contd..2), H1 2015 295

Cervical Cancer-Dormant Projects (Contd..3), H1 2015 296

Cervical Cancer-Discontinued Products, H1 2015 297

List of Figures

Number of Products under Development for Cervical Cancer, H1 2015 17

Number of Products under Development for Cervical Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 83

Assessment by Combination Products, H1 2015 84

Number of Products by Top 10 Targets, H1 2015 85

Number of Products by Stage and Top 10 Targets, H1 2015 85

Number of Products by Top 10 Mechanism of Actions, H1 2015 89

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 89

Number of Products by Top 10 Routes of Administration, H1 2015 92

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 92

Number of Products by Top 10 Molecule Types, H1 2015 94

Number of Products by Stage and Top 10 Molecule Types, H1 2015 94

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Admedus Ltd

Advaxis, Inc.

Amorfix Life Sciences Ltd.

Antigen Express, Inc.

Arbor Vita Corporation

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Azaya Therapeutics Incorporated

Cancer Research Technology Limited

Chong Kun Dang Pharmaceutical Corp.

Critical Outcome Technologies Inc.

CZ BioMed Corp

Daiichi Sankyo Company, Limited

EyeGene, Inc.

F. Hoffmann-La Roche Ltd.

Formune S.L.

Genexine, Inc.

Genmab A/S

Genticel S.A.

GlaxoSmithKline Plc

Indian Immunologicals Limited

Inovio Pharmaceuticals, Inc.

ISA Pharmaceuticals B.V.

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

LondonPharma Ltd

MedImmune, LLC

MEI Pharma, Inc.

Nanotherapeutics, Inc.

Nektar Therapeutics

Novartis AG

Oncobiologics, Inc.

Otsuka Holdings Co., Ltd.

Redbiotec AG

Rexahn Pharmaceuticals, Inc.

Sanofi

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Shantha Biotechnics Limited

Sirnaomics, Inc.

Taiho Pharmaceutical Co., Ltd.

Theravectys S.A.

Vaccibody AS

VLPbio

Zeria Pharmaceutical Co Ltd

Zydus Cadila Healthcare Limited

Cervical Cancer Therapeutic Products under Development, Key Players in Cervical Cancer Therapeutics, Cervical Cancer Pipeline Overview, Cervical Cancer Pipeline, Cervical Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com